Literature DB >> 34673115

Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies.

Krishnamoorthi Sumaiya1, Dianne Langford2, Kalimuthusamy Natarajaseenivasan3, Santhanam Shanmughapriya4.   

Abstract

Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine encoded within a functionally polymorphic genetic locus. MIF was initially recognized as a cytokine generated by activated T cells, but in recent days it has been identified as a multipotent key cytokine secreted by many other cell types involved in immune response and physiological processes. MIF is a highly conserved 12.5 kDa secretory protein that is involved in numerous biological processes. The expression and secretion profile of MIF suggests that MIF to be ubiquitously and constitutively expressed in almost all mammalian cells and is vital for numerous physiological processes. MIF is a critical upstream mediator of host innate and adaptive immunity and survival pathways resulting in the clearance of pathogens thus playing a protective role during infectious diseases. On the other hand, MIF being an immune modulator accelerates detrimental inflammation, promotes cancer metastasis and progression, thus worsening disease conditions. Several reports demonstrated that genetic and physiological factors, including MIF gene polymorphisms, posttranslational regulations, and receptor binding control the functional activities of MIF. Taking into consideration the multi-faceted role of MIF both in physiology and pathology, we thought it is timely to review and summarize the expressional and functional regulation of MIF, its functional mechanisms associated with its beneficial and pathological roles, and MIF-targeting therapies. Thus, our review will provide an overview on how MIF is regulated, its response, and the potency of the therapies that target MIF.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epigenetic regulation; Genetic polymorphisms; MIF receptors; MIF targeting therapy; Multifaceted MIF; Posttranslational modifications

Mesh:

Substances:

Year:  2021        PMID: 34673115     DOI: 10.1016/j.pharmthera.2021.108024

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   13.400


  7 in total

1.  Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study.

Authors:  Rafał Watrowski; Eva Obermayr; Christine Wallisch; Stefanie Aust; Nicole Concin; Elena Ioana Braicu; Toon Van Gorp; Annette Hasenburg; Jalid Sehouli; Ignace Vergote; Robert Zeillinger
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

2.  Single-cell atlas of peripheral blood mononuclear cells from pregnant women.

Authors:  Dongsheng Chen; Wei Wang; Linlin Wu; Langchao Liang; Shiyou Wang; Yunfeng Cheng; Tongda Zhang; Chaochao Chai; Qiuhong Luo; Chengcheng Sun; Wandong Zhao; Zhiyuan Lv; Ya Gao; Xiaoxia Wu; Ning Sun; Yiwei Zhang; Jing Zhang; Yixuan Chen; Jianing Tong; Xiangdong Wang; Yong Bai; Chaoyang Sun; Xin Jin; Jianmin Niu
Journal:  Clin Transl Med       Date:  2022-05

3.  Identification of novel tumor microenvironment-associated genes in gastric cancer based on single-cell RNA-sequencing datasets.

Authors:  Xujin Wei; Jie Liu; Zhijun Hong; Xin Chen; Kang Wang; Jianchun Cai
Journal:  Front Genet       Date:  2022-08-15       Impact factor: 4.772

4.  Difference in macrophage migration inhibitory factor between preterm and term newborns and associating clinical factors: Preliminary study.

Authors:  Ji Sook Park; Jin Su Jun; Jae Young Cho; Jung Sook Yeom; Ji-Hyun Seo; Jae Young Lim; Chan-Hoo Park; Hyang-Ok Woo; Hee-Shang Youn
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

Review 5.  Macrophage migration inhibitory factor in acute kidneyinjury.

Authors:  Yiwei Du; Hao Hao; Heng Ma; Hongbao Liu
Journal:  Front Physiol       Date:  2022-09-02       Impact factor: 4.755

6.  Pharmacologic inhibition of MIF nuclease: A new treatment paradigm to treat cell death.

Authors:  Devanik Biswas; Valina L Dawson; Ted M Dawson
Journal:  Clin Transl Med       Date:  2022-09

Review 7.  OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases.

Authors:  Michael Thiele; Seamas C Donnelly; Robert A Mitchell
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.